(redirected from polycythemia)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to polycythemia: polycythemia vera, secondary polycythemia

SECONDARY, construction. That which comes after the first, which is primary: as, the primary law of, nations the secondary law of nations.

SECONDARY, English law. An officer who is second or next to the chief officer; as secondaries to the prothonotaries of the courts of king's bench, or common pleas; secondary of the remembrancer in the exchequer, &c. Jacob, L. D. h.t.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
This European approval makes Besremi the first and only approved treatment for polycythemia vera (PV) independent of previous hydroxyurea exposure based on Phase III clinical data.
A complete blood count showed polycythemia, with red blood cell (RBC): 5.7x[10.sup.6]/[mm.sup.3] (4.1-5.2 x[10.sup.6]/[mm.sup.3]), hemoglobin: 17.2g/dL (12.8-15.0 g/dL), hematocrit: 51% (37.3-47.3%), mean corpuscular volume: 90 fL (81.4-91.9 fL).
Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Polycythemia can be asymptomatic and therefore undiagnosed for many years, leading to its discovery as an incidental finding (1).
Germline mutations in PHD1/2 were reported in patients with polycythemia and PHEO/PGL [17, 53].
His past medical history was significant for heart failure with reduced ejection fraction, polycythemia vera, obstructive sleep apnea, hypertension, hyperlipidemia, aortic stenosis, anemia, chronic kidney disease stage IV, and stroke.
Alvarez-Larran, "How to Treat Essential Thrombocythemia and Polycythemia Vera," Clinical Lymphoma, Myeloma & Leukemia, vol.
The patient had an increased hematocrit (64%) 12 years ago, leading to clinical suspicion of polycythemia, although the patient was quickly lost to follow-up.
A neonate with subcutaneous fat necrosis after passive cooling: does polycythemia have an effect?
Treatment with pazopanib and other VEGFR TKIs can induce secondary polycythemia. Awareness of this and attention to blood counts and symptoms suggesting erythrocytosis are important in monitoring RCC patients receiving these therapies.
The term myeloproliferative neoplasms (MPN) was first introduced by William Dameshek in 1951 to emphasize the clinicopathological similarities between chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and myeloid metaplasia (MMM) (Also known as, chronic idiopathic myelofibrosis or primary myelofibrosis).2 Accordingly, these 4 disorders are currently referred to as "classic" MPN.
Hence, the aim of the current study was to demonstrate whether curcumin treatment could attenuate the effect of recombinant human EPO on erythropoiesis in EPO-induced polycythemia, and if so, whether this effect is mediated by changing iron and hepcidin concentrations in rats.